Funding
MH, HT
This study was funded by the National Institute of Mental Health (NIMH) R01MH099167 grant (ANV). The STOP-PD II clinical trial from which participants were recruited was funded by US Public Health Service grants MH 62446 (AJF), MH 62518 (BSM), MH 62565 (EMW), and MH 62624 (AJR) from the NIMH. In that trial, Eli Lilly provided olanzapine and matching placebo pills and Pfizer provided sertraline; neither company provided funding for the study. This work was supported in part by a Postdoctoral Fellowship from the Canadian Institutes of Health Research (HT).